0.00Open0.03Pre Close0 Volume2.74K Open Interest12.50Strike Price0.00Turnover0.00%IV214.82%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-21DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma132.67Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Biomea Fusion Stock Discussion
Icovamenib, in combination with semaglutide, approximately doubled C-peptide production per unit of glucose compared to semaglutide alone leading to a 60% improved reduction of fasting blood glucose
Ex vivo human islet experiments pr...
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study Thanks @Jaguar8 For spotting since for some reason they say no more posts???
Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient population
Icovamenib was well-tolerated, with no adverse-event related discontinuations, no hypoglycemic events and no serious adverse events
Yet all the analysts are giving target price from a low 11$ to a 50/60 and above.
What's your take?
No comment yet